BioNTech SE Sponsored ADR (NASDAQ:BNTX) Stock Has Average Price Target of $126.00

BioNTech SE Sponsored ADR (NASDAQ:BNTX) has received a consensus rating of “Moderate Buy” from the twenty research firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, six have given a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $125.69.

Several research analysts have recently issued reports on the stock. Argus began coverage on shares of BioNTech in a report on Thursday. They issued a “hold” rating on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioNTech in a report on Friday, October 2nd. BMO Capital Markets cut shares of BioNTech from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $128.00 to $105.00 in a research report on Tuesday, September 8th. Canaccord Genuity Group cut their price target on shares of BioNTech from $142.00 to $136.00 and set a “buy” rating on the stock in a report on Monday, August 31st. Finally, Wall Street Zen cut shares of BioNTech from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th.

BioNTech Trading Up 5.3%

Shares of BNTX stock opened at $96.96 on Friday. The stock has a market capitalization of $24.52 billion, a PE ratio of -12.38 and a beta of 1.25. BioNTech has a 1-year low of $79.52 and a 1-year high of $124.00. The business has a 50-day moving average of $99.17 and a 200 day moving average of $95.17. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%. The company had revenue of $122.31 million during the quarter, compared to analysts’ expectations of $180.18 million. During the same period last year, the firm earned ($1.60) earnings per share. BioNTech’s revenue for the quarter was down 59.5% on a year-over-year basis. As a group, sell-side analysts anticipate that BioNTech will post -6.37 earnings per share for the current year.

Insider Buying and Selling at BioNTech

In related news, CEO Ugur Sahin sold 36,209 shares of the firm’s stock in a transaction dated Friday, October 9th. The stock was sold at an average price of $95.37, for a total value of $3,453,252.33. Following the sale, the chief executive officer directly owned 36,209 shares of the company’s stock, valued at $3,453,252.33. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 807,209 shares of company stock worth $79,246,837 in the last ninety days. Corporate insiders own 19.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of BNTX. Farther Finance Advisors LLC grew its position in shares of BioNTech by 31.5% in the 3rd quarter. Farther Finance Advisors LLC now owns 493 shares of the company’s stock worth $48,000 after buying an additional 118 shares during the last quarter. Quintet Private Bank Europe S.A. increased its stake in shares of BioNTech by 232.8% during the third quarter. Quintet Private Bank Europe S.A. now owns 1,917 shares of the company’s stock valued at $188,000 after buying an additional 1,341 shares during the period. Engineers Gate Manager LP raised its holdings in shares of BioNTech by 17.3% during the second quarter. Engineers Gate Manager LP now owns 12,433 shares of the company’s stock valued at $1,157,000 after acquiring an additional 1,833 shares in the last quarter. Integrated Wealth Concepts LLC bought a new position in shares of BioNTech during the second quarter valued at approximately $39,000. Finally, Nykredit A S purchased a new stake in BioNTech in the second quarter worth $293,000. Institutional investors own 15.52% of the company’s stock.

Key Headlines Impacting BioNTech

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: Biotech-sector momentum offered a modest tailwind after Moderna’s inclusion in the Nasdaq-100 triggered a sharp move in its shares, while BioNTech also traded higher alongside other major vaccine companies. Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up
• Neutral Sentiment: Argus initiated coverage with a Hold rating, adding a cautious view but no immediate change to the company’s fundamentals. Argus coverage reference
• Neutral Sentiment: A report stating that short interest totaled zero shares implies no measurable short-squeeze pressure. The figure may reflect a reporting or data issue and should be interpreted cautiously.
• Negative Sentiment: CEO Ugur Sahin sold 36,209 shares for approximately $3.45 million on October 9 and another 27,000 shares for about $2.49 million on October 8. The transactions were executed under a pre-arranged Rule 10b5-1 plan, which reduces their significance as discretionary signals, but the sales substantially reduced his direct ownership. BioNTech CEO SEC filing
• Negative Sentiment: The latest quarterly results showed continuing commercial pressure: revenue fell 59.5% year over year to $122.31 million, below the $180.18 million consensus estimate, while the company reported a loss of $2.53 per share. Analysts expect a full-year loss, underscoring the need for BioNTech’s pipeline to offset declining COVID-19 vaccine revenue.

BioNTech Company Profile

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company’s research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.